Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
223 hedge funds and large institutions have $2.75B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2015 Q3 according to their latest regulatory filings, with 64 funds opening new positions, 76 increasing their positions, 74 reducing their positions, and 52 closing their positions.
112% more call options, than puts
Call options by funds: $160M | Put options by funds: $75.7M
23% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 52
5% more funds holding
Funds holding: 213 → 223 (+10)
3% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 74
38% less capital invested
Capital invested by funds: $4.41B → $2.75B (-$1.66B)
67% less funds holding in top 10
Funds holding in top 10: 18 → 6 (-12)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
+$392M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$61M |
| 3 |
BC
Broadfin Capital
New York
|
+$58.4M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$42.3M |
| 5 |
D.E. Shaw & Co
New York
|
+$40.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$132M |
| 2 |
HM
HealthCor Management
New York
|
-$111M |
| 3 |
KCM
Kingdon Capital Management
New York
|
-$65.6M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$48.4M |
| 5 |
LCM
LionEye Capital Management
New York
|
-$48M |
HZNP Hedge Fund Activity: Q3 2015 in Review
223 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2015, worth a combined $2.75B — down 38% from $4.41B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new HZNP positions and 52 closed out — a net gain of 12 holders — while 76 added to existing stakes and 74 trimmed.
The largest buyer was Lone Pine Capital, adding an estimated $392M. The largest seller was Deerfield Management, cutting an estimated $132M.
- 223 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2015, up from 213 in Q2 2015.
- Funds reported $2.75B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2015, down 38% quarter-over-quarter.
- 64 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2015 and 52 closed out, a net change of +12 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2015 was Lone Pine Capital, an estimated $392M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2015 was Deerfield Management, an estimated $132M sold.
Based on aggregated 13F filings for Q3 2015.